We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand Dermatitis

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00828464
First Posted: January 26, 2009
Last Update Posted: October 3, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
GlaxoSmithKline ( Stiefel, a GSK Company )
Results First Submitted: April 7, 2010  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Hand Dermatosis
Intervention: Drug: clobetasol propionate

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
  • Recruitment period: First Subject Enrolled October 2008, Last Subject Enrolled January 2009.
  • Type of location: Dermatology Research Center

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
  1. Washout from use of systemic corticosteroid and/or other prohibited medications if used within 4 weeks of the baseline visit.
  2. Washout from use of topical corticosteroid therapy and/or other prohibited topical medications if used within 2 weeks prior to the baseline visit

Reporting Groups
  Description
Clobetasol Propionate Foam All subjects applied clobetasol propionate 0.05% foam twice a day (morning and evening) to the hands.

Participant Flow:   Overall Study
    Clobetasol Propionate Foam
STARTED   30 
COMPLETED   29 
NOT COMPLETED   1 
Withdrawal by Subject                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Clobetasol Propionate Foam All subjects applied clobetasol propionate 0.05% foam twice a day (morning and evening) to the hands.

Baseline Measures
   Clobetasol Propionate Foam 
Overall Participants Analyzed 
[Units: Participants]
 30 
Age 
[Units: Participants]
 
<=18 years   0 
Between 18 and 65 years   30 
>=65 years   0 
Age 
[Units: Years]
Mean (Standard Deviation)
 47.5  (14.9) 
Gender 
[Units: Participants]
 
Female   16 
Male   14 
Region of Enrollment 
[Units: Participants]
 
United States   30 
ISGA-Chronic Hand Dermatitis [1] 
[Units: Participants]
 
Mild   16 
Moderate   14 
[1] Investigators Static Global Assessment (ISGA)- Chronic Hand Dermatitis Score=2 mild Score=3 moderate These are the only scores that are permitted for entry on this study.
Time since Diagnosis of Chronic Hand Dermatitis (years) [1] 
[Units: Years]
Mean (Standard Deviation)
 18.92  (15) 
[1] Time since Diagnosis of Chronic Hand Dermatitis, Allergic, Irritant or Contact Dermatitis (years)
Total Hand Eczema Severity Index (HESI) [1] 
[Units: Units on a scale]
Mean (Standard Deviation)
 32.1  (17.0) 
[1] Total Hand Eczema Severity Index (total HESI) Score 0 to 360 where 0 is the best and 360 is the worst score.


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Proportion of Subjects With at Least 1-grade Improvement From Baseline to Day 15 in Investigator's Static Global Assessment Score (ISGA) Score   [ Time Frame: Baseline, Day 15 ]

2.  Secondary:   Proportion of Subjects Who Achieve at Least a 1-grade Improvement Based on the ISGA at Day 8.   [ Time Frame: Baseline, Day 8 ]

3.  Secondary:   Change in Subject’s Visual Analogue Assessment Scale   [ Time Frame: Baseline, Day 8 ]

4.  Secondary:   Proportion of Subjects at Day 15 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Finger Tips   [ Time Frame: Baseline, Day 15 ]

5.  Secondary:   Proportion of Subjects at Day 8 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Finger Tips   [ Time Frame: Baseline, Day 8 ]

6.  Secondary:   Proportion of Subjects at Day 15 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline - Fingers   [ Time Frame: Baseline, Day 15 ]

7.  Secondary:   Proportion of Subjects With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Fingers   [ Time Frame: Baseline, Day 8 ]

8.  Secondary:   Proportion of Subjects at Day 8 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Palm of Hands   [ Time Frame: Baseline, Day 8 ]

9.  Secondary:   Proportion of Subjects at Day 15 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Palm of Hands   [ Time Frame: Baseline, Day 15 ]

10.  Secondary:   Proportion of Subjects at Day 8 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Back of Hands   [ Time Frame: Baseline, Day 8 ]

11.  Secondary:   Proportion of Subjects at Day 15 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Back of Hands   [ Time Frame: Baseline, Day 15 ]

12.  Secondary:   Proportion of Subjects at Day 8 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Wrists   [ Time Frame: Baseline, Day 8 ]

13.  Secondary:   Proportion of Subjects at Day 15 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Wrists   [ Time Frame: Baseline, Day 15 ]

14.  Secondary:   Change in Subject’s Visual Analogue Assessment Scale From Baseline to Day 15   [ Time Frame: Baseline, Day 15 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Open label study


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: GSK Response Center
Organization: GlaxoSmithKline
phone: 866-435-7343


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: GlaxoSmithKline ( Stiefel, a GSK Company )
ClinicalTrials.gov Identifier: NCT00828464     History of Changes
Other Study ID Numbers: U0280-401
First Submitted: January 22, 2009
First Posted: January 26, 2009
Results First Submitted: April 7, 2010
Results First Posted: September 28, 2010
Last Update Posted: October 3, 2012